Knutson KL - Search Results

1

Immunotherapeutic approaches for the treatment of breast cancer.

Knutson KL, Schiffman K, Rinn K, Disis ML. Knutson KL, et al. J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):353-65. doi: 10.1023/a:1018714300217. J Mammary Gland Biol Neoplasia. 1999. PMID: 10705919 Review.

2

Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization.

Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Disis ML, et al. Among authors: knutson kl. Clin Cancer Res. 2000 Apr;6(4):1347-50. Clin Cancer Res. 2000. PMID: 10778962

3

Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer.

Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Disis ML, et al. Among authors: knutson kl. Breast Cancer Res Treat. 2000 Aug;62(3):245-52. doi: 10.1023/a:1006438507898. Breast Cancer Res Treat. 2000. PMID: 11072789

4

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.

Knutson KL, Schiffman K, Disis ML. Knutson KL, et al. J Clin Invest. 2001 Feb;107(4):477-84. doi: 10.1172/JCI11752. J Clin Invest. 2001. PMID: 11181647 Free PMC article.

5

Clinical translation of peptide-based vaccine trials: the HER-2/neu model.

Disis ML, Knutson KL, McNeel DG, Davis D, Schiffman K. Disis ML, et al. Among authors: knutson kl. Crit Rev Immunol. 2001;21(1-3):263-73. Crit Rev Immunol. 2001. PMID: 11642608 Review.

6

Adoptive T-cell therapy for the treatment of solid tumours.

Knutson KL, Almand B, Mankoff DA, Schiffman K, Disis ML. Knutson KL, et al. Expert Opin Biol Ther. 2002 Jan;2(1):55-66. doi: 10.1517/14712598.2.1.55. Expert Opin Biol Ther. 2002. PMID: 11772340 Review.

7

Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.

Knutson KL, Disis ML. Knutson KL, et al. Clin Breast Cancer. 2001 Apr;2(1):73-9. doi: 10.3816/CBC.2001.n.014. Clin Breast Cancer. 2001. PMID: 11899386 Review.

8

Vaccination against the HER-2/neu oncogenic protein.

Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML. Bernhard H, et al. Among authors: knutson kl. Endocr Relat Cancer. 2002 Mar;9(1):33-44. doi: 10.1677/erc.0.0090033. Endocr Relat Cancer. 2002. PMID: 11914181 Review.

9

Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers.

Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, Schiffman K. Disis ML, et al. Among authors: knutson kl. Blood. 2002 Apr 15;99(8):2845-50. doi: 10.1182/blood.v99.8.2845. Blood. 2002. PMID: 11929774 Free article. Clinical Trial.

10

Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.

Knutson KL, Schiffman K, Cheever MA, Disis ML. Knutson KL, et al. Clin Cancer Res. 2002 May;8(5):1014-8. Clin Cancer Res. 2002. PMID: 12006513 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

289 results

Search Page

Filters